| Gene Symbol | APOE |
| Full Name | Expressing Astrocytes |
| Chromosome | 19q13.32 |
| Target Class | Ligand |
| Function | It binds to the LDL receptor family to facilitate uptake of lipoprotein particles. |
| Mechanism of Action | Protein-protein interaction modulator or lipid metabolism enhancer |
| Druggability | Medium (0.47) |
| Clinical Stage | Phase II |
| Molecular Weight | 34 kDa |
| Pathways | Amyloid, Autophagy, Blood-Brain Barrier, Brain Lipid Metabolism, Cholesterol |
| GeneCards | APOE |
| Human Protein Atlas | APOE |
| Cell Type | Astrocyte (glial cell) |
| Marker Genes | APOE, GFAP, ALDH1L1, GLT1 (SLC1A2) |
| Neurotransmitter | Not applicable (metabolic support) |
| Associated Diseases | AD, Age Of Onset, Aging, alpha-synucleinopathies, Als |
| Known Drugs/Compounds | atherogenic lipoproteins, Crispr, curcumin, CURCUMIN |
| Interactions | A2M, ABC7 transporter, ABCA1, abca2, ABCA2, ABCA7 |
| SciDEX Target | View Target Profile (8 clinical trials) |
| SciDEX Hypotheses | Prime Editing Precision Correction of APOE4 to APO Selective APOE4 Degradation via Proteolysis Target Competitive APOE4 Domain Stabilization Peptides (+25 more) |
| KG Connections | 4626 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!